The Kampo Medicine Goshajinkigan Prevents Neuropathy in Breast Cancer Patients Treated with Docetaxel

  • Abe, Hajime (Breast Center, Bell Land General Hospital) ;
  • Kawai, Yuki (Division of Breast and General Surgery, Shiga University of Medical Science Hospital) ;
  • Mori, Tsuyoshi (Division of Breast and General Surgery, Shiga University of Medical Science Hospital) ;
  • Tomida, Kaori (Division of Breast and General Surgery, Shiga University of Medical Science Hospital) ;
  • Kubota, Yoshihiro (Division of Breast and General Surgery, Shiga University of Medical Science Hospital) ;
  • Umeda, Tomoko (Division of Breast and General Surgery, Shiga University of Medical Science Hospital) ;
  • Tani, Tohru (Department of Surgery, Shiga University of Medical Science)
  • Published : 2013.11.30


Background: Goshajinkigan (GJG) is used for the treatment of several neurological symptoms. We investigated the efficacy of GJG and mecobalamin (B12) against neurotoxicity associated with docetaxel (DOC) in breast cancer patients. Materials and Methods: Sixty breast cancer patients were treated with DOC. Thirty-three patients (GJG group) received oral administration of 7.5 g/day GJG and 27 patients (B12 group) received oral administration of 1500 ${\mu}g/day$ B12. Neuropathy was evaluated according to DEB-NTC (Neurotoxicity Criteria of Debiopharm), Common Terminology Criteria for Adverse Events (NCI-CTC) ver. 3.0, and a visual analogue scale (VAS). This study employed a randomized open design. Results: The incidence of neuropathy was 39.3% in the GJG group, and 88.9% in the B12 group (p<0.01). In the GJG group, grade 1 DEB-NTC was observed in 2 cases, grade 2 in 5 cases and grade 3 in 5 cases. Grade 1 NCI-CTC was observed in 7 cases, grade 2 in 6 cases, and VAS was $2.7{\pm}2.2$. In the B12 group, grades 1, 2 and 3 DEB-NTC were observed in one case, 12 cases and 12 cases, respectively; and grades 1, 2 and 3 NCI-CTC were observed in 11 cases, 12 cases and one case, and VAS was $4.9{\pm}2.4$. Conclusions: Concomitant administration of GJG is useful in preventing neuropathy in breast cancer patients treated with a DOC regimen.


Breast cancer;goshajinkigan;docetaxel;peripheral neuropathy;mecobalamin


  1. Argyriou AA, Koltzenburg M, Polychronopoulos P, et al (2008). Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol, 66, 218-28.
  2. Calhoun EA, Welshman EE, Chang CH, et al (2003). Psychometric evaluation of the functional assessment of cancer therapy/gynecologic oncology group-neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer, 13, 741-8.
  3. Carlson K, Ocean AJ (2011). Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach. Clin Breast Cancer, 11, 73-81.
  4. De Laurentiis M, Cancello G, D’Agostino D, et al (2008). Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol, 26, 44-53.
  5. Gilron I, Bailey JM, Tu D, et al (2005). Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med, 352, 1324-34.
  6. Gotoh A, Goto K, Sengoku A, et al (2004). Inhibition mechanism of Gosha-jinki-gan on the micturition reflex in rats. J Pharmacol Sci, 96, 115-23.
  7. Hausheer FH, Schilsky RL, Bain S, et al (2006). Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol, 33, 15-49.
  8. Henderson IC, Berry DA, Demetri GD, et al (2003). Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol, 21, 976-83.
  9. Hu X, Sato J, Oshida Y, et al (2003). Effect of Gosha-jinki-gan (Chinese herbal medicine: Niu-Che-Sen-Qi-Wan) on insulin resistance in streptozotocin-induced diabetic rats. Diabetes Res Clin Pract, 59, 103-11.
  10. Huskisson EC (1974). Measurement of pain. Lancet, 2, 1127-31.
  11. Imamura T, Ishizuka O, Aizawa N, et al (2008). Gosha-jinki-gan reduces transmitter proteins and sensory receptors associated with C fiber activation induced by acetic acid in rat urinary bladder. Neurourol Urodyn, 27, 832-7.
  12. Inoue N, Ishida H, Sano M, et al (2011). Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer. Int J Clin Oncol, 17, 341-7.
  13. Jones SE, Erban J, Overmoyer B, et al (2005). Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol, 23, 5542-51.
  14. Katsumata N, Noda K, Nozawa S, et al (2005). Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study. Br J Cancer, 93, 999-1004.
  15. Kono T, Mamiya N, Chisato N, et al (2011). Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer. Evid Based Complement Alternat Med, 2011, 418481..
  16. Kuwabara S, Nakazawa R, Azuma N, et al (1999). Intravenous methylcobalamin treatment for uremic and diabetic neuropathy in chronic hemodialysis patients. Intern Med, 38, 472-5.
  17. Lee JJ, Swain SM (2006). Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol, 24, 1633-42.
  18. Muro K, Hamaguchi T, Ohtsu A, et al (2004). A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol, 15, 955-9.
  19. Nagaki Y, Hayasaka S, Hayasaka Y, et al (2003). Effects of goshajinkigan on corneal sensitivity, superficial punctate keratopathy and tear secretion in patients with insulin-dependent diabetes mellitus. Am J Chin Med, 31, 103-9.
  20. Naito S, Tsukamoto T, Koga H, et al (2008). Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan. Jpn J Clin Oncol, 38, 365-72
  21. Nishioka M, Shimada M, Kurita N, et al (2011). The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. Int J Clin Oncol, 16, 322-7.
  22. Postma TJ, Aaronson NK, Heimans JJ, et al (2005). The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer, 41, 1135-9.
  23. Rao RD, Flynn PJ, Sloan JA, et al (2008). Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer, 112, 2802-8.
  24. Ravdin PM, Burris HA 3rd, Cook G, et al (1995). Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol, 13, 2879-85.
  25. Roche H, Fumoleau P, Spielmann M, et al (2006). Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol, 24, 5664-71.
  26. Smith TJ, Staats PS, Deer T, et al (2002). Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol, 20, 4040-9.
  27. Sparano JA, Wang M, Martino S, et al (2008). Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med, 358, 1663-71.
  28. Stubblefield MD, Burstein HJ, Burton AW, et al (2009). NCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw, 7, 1-26.
  29. Swain SM, Arezzo JC (2008). Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol, 6, 455-67.
  30. Takemoto S, Ushijima K, Honda K, et al (2012). Precise evaluation of chemotherapy-induced peripheral neuropathy using the visual analogue scale: a quantitative and comparative analysis of neuropathy occurring with paclitaxel-carboplatin and docetaxel-carboplatin therapy. Int J Clin Oncol, 17, 367-72.
  31. Trotti A, Colevas AD, Setser A, et al (2003). CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol, 13, 176-81.
  32. Uno T, Ohsawa I, Tokudome M, et al (2005). Effects of Goshajinkigan on insulin resistance in patients with type 2 diabetes. Diabetes Res Clin Pract, 69, 129-35.
  33. Yamada K, Suzuki E, Nakaki T, et al (2005). Aconiti tuber increases plasma nitrite and nitrate levels in humans. J Ethnopharmacol, 96, 165-9.

Cited by

  1. Complementary Alternative Medicine Use Amongst Breast Cancer Patients in the Northern Region of Peninsular Malaysia vol.16, pp.8, 2015,
  2. Analgesic Herbs vol.23, pp.6, 2017,
  3. Prophylactic Administration of Aucubin Inhibits Paclitaxel-Induced Mechanical Allodynia via the Inhibition of Endoplasmic Reticulum Stress in Peripheral Schwann Cells vol.40, pp.4, 2017,
  4. Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis pp.1437-7772, 2017,
  5. A Systematic Review of Herbal Medicine for Chemotherapy Induced Peripheral Neuropathy vol.2018, pp.1741-4288, 2018,
  6. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis vol.26, pp.4, 2018,